Tarsus to acquire Alkeus, iRenix

Tarsus Pharmaceuticals is entering the retina space with deals to acquire Alkeus Pharmaceuticals and iRenix Medical, according to press releases.The acquisitions are focused on two therapies: gildeuretinol (ALK-001, Alkeus Pharmaceuticals) and IRX-101 (iRenix Medical). Gildeuretinol is an investigational once-daily oral therapy for the treatment of Stargardt disease designed to reduce damage to

Raccontata dahealio.com